PMID- 36082491
OWN - NLM
STAT- MEDLINE
DCOM- 20230224
LR  - 20230226
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 3
DP  - 2023 Feb
TI  - A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as 
      second-line treatment in advanced small cell lung cancer.
PG  - 2979-2989
LID - 10.1002/cam4.5217 [doi]
AB  - INTRODUCTION: Currently, only a few options are available for the treatment of 
      patients with small-cell lung cancer (SCLC) after the failure of first-line 
      platinum-based chemotherapy. The present study aimed to evaluate the efficacy and 
      safety of apatinib plus chemotherapy for second-line treatment of advanced SCLC. 
      PATIENTS AND METHODS: This prospective clinical trial recruited patients treated 
      with apatinib plus second-line chemotherapy until disease progression or 
      intolerable toxicity. Logrank test power analysis was used for calculating 
      samples. The primary endpoint was progression-free survival (PFS), and the 
      secondary endpoints were objective response rate (ORR), disease control rate 
      (DCR), overall survival (OS), and safety. RESULTS: A total of 29/31 enrolled 
      patients were available for response evaluation until October 2019. The ORR and 
      DCR were 27.59% (8/29) and 96.55% (28/29), respectively. The median PFS and OS 
      were 7.36 months and 14.16 months, respectively, indicating better efficacy 
      compared with the standard second-line chemotherapies. The most common adverse 
      events (AEs) were neutropenia (41.94%, 13/31), followed by leucopenia (35.48%, 
      11/31) and thrombocytopenia (25.81%, 8/31). The grade 3-4 AEs occurred in 12 
      (38.71%) patients, of which neutropenia (19.35%, 6/31), leucopenia (9.68%, 3/31), 
      and proteinuria (6.45%, 2/31) were most common. Patients receiving an initial 
      dose of apatinib 250 mg had a better tolerance. CONCLUSION: Antiangiogenic 
      therapy plus chemotherapy had encouraging efficacy in advanced SCLC patients, 
      which provides an insight into the current status of second-line therapy in SCLC.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Xu, Yinghui
AU  - Xu Y
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Wang, Xu
AU  - Wang X
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Sun, Chao
AU  - Sun C
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Gao, Zhiru
AU  - Gao Z
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - He, Hua
AU  - He H
AUID- ORCID: 0000-0003-0015-8396
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Qiu, Shi
AU  - Qiu S
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Guo, Ye
AU  - Guo Y
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Ma, Xiaohui
AU  - Ma X
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Song, Junya
AU  - Song J
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Ma, Kewei
AU  - Ma K
AUID- ORCID: 0000-0003-2987-576X
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220909
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 5S371K6132 (apatinib)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - *Small Cell Lung Carcinoma/drug therapy
MH  - *Lung Neoplasms/drug therapy
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Neutropenia/chemically induced
PMC - PMC9939110
OTO - NOTNLM
OT  - VEGFR2
OT  - angiogenesis
OT  - apatinib
OT  - small cell lung cancer (SCLC)
OT  - targeted therapy
COIS- The authors declare that they have no conflicts of interest or competing 
      interests.
EDAT- 2022/09/10 06:00
MHDA- 2023/02/25 06:00
PMCR- 2022/09/09
CRDT- 2022/09/09 03:23
PHST- 2022/08/03 00:00 [revised]
PHST- 2022/05/29 00:00 [received]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2022/09/10 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2022/09/09 03:23 [entrez]
PHST- 2022/09/09 00:00 [pmc-release]
AID - CAM45217 [pii]
AID - 10.1002/cam4.5217 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Feb;12(3):2979-2989. doi: 10.1002/cam4.5217. Epub 2022 Sep 9.